Dublin, Aug. 19, 2024 (GLOBE NEWSWIRE) -- The "Epinephrine Auto-Injection Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.
The Epinephrine Auto-Injection Market was valued at USD 2.05 billion in 2023, and is expected to reach USD 3.40 billion by 2029, rising at a CAGR of 8.80%
The global epinephrine auto-injector market report contains exclusive data on 14 vendors. The global epinephrine auto-injector market is highly consolidated and is characterized by a few established vendors holding most of the market share.
Vendors are offering several branded and generic epinephrine auto-injectors. They compete based on regulatory approvals, safety features, accurate dosing, convenient use, technology up-gradation, marketing strategies, and distribution channels. Viatris (Mylan), Teva Pharmaceuticals, Amneal Pharmaceuticals, Bausch & Lomb, and ALK Abello are the key vendors in the market. These companies have a wide geographic footprint, diversified product portfolio, and a strong focus on innovation and research activities.
North America accounted for over 79% of the share and stands first in the global epinephrine auto-injector market. The market in the region is dominated by branded and generic epinephrine auto-injectors for treating anaphylactic reactions. The availability of generic epinephrine auto-injectors is abundantly high in this region. The increasing prevalence of anaphylaxis and high healthcare spending enables high uptake of epinephrine auto-injectors as self-medication or through the recommendation of healthcare professionals.
MARKET TRENDS & DRIVERS
Increasing Demand for Epinephrine Auto-injectors at Pharma/Retail stores
The increasing demand for generic epinephrine auto-injectors at pharmaceutical and retail stores reflects a growing awareness of the importance of accessibility and affordability in emergency medical care. As more individuals recognize the need for epinephrine to manage allergic emergencies such as anaphylaxis, there is a heightened demand for cost-effective alternatives to brand-name auto-injectors.
Generic epinephrine auto-injectors offer a more affordable option for patients, particularly those without adequate insurance coverage or facing high out-of-pocket costs. As a result, pharmaceutical and retail stores are witnessing a surge in consumer demand for these generic alternatives. Patients actively seek out these products to access life-saving medication without financial burden. Moreover, the increased availability of generic epinephrine auto-injectors at pharmaceutical and retail stores is driven by efforts to expand access to essential medications.
Additionally, the convenience and accessibility of purchasing generic epinephrine auto-injectors at retail stores further increase demand. Overall, the increasing demand for generic epinephrine auto-injectors at pharmaceutical and retail stores underscores the importance of affordability and accessibility in emergency medical care. By providing cost-effective alternatives to brand-name auto-injectors, generic products help ensure that all individuals at risk of anaphylaxis have access to the life-saving medication they need to manage allergic emergencies effectively.
Customization and Personalization of Epinephrine Auto-injectors
Customization and personalization of epinephrine auto-injectors represent a significant opportunity for enhancing patient experience and improving treatment outcomes. One customization aspect involves dosage adjustments, where auto-injectors can offer adjustable dosage options to cater to individuals with varying sensitivity to allergens or specific medical needs. This flexibility ensures that patients receive the appropriate dose of epinephrine tailored to their unique requirements, optimizing treatment efficacy. Additionally, customizing the form factor and design of auto-injectors can improve usability and acceptance among different patient groups.
The Rise of Generic Epinephrine Auto-injectors
The availability of generic versions of epinephrine auto-injectors has been a positive development in improving access to life-saving medication for individuals at risk of severe allergic reactions. Generic versions typically offer more affordable alternatives to brand-name auto-injectors, making them more accessible to a broader range of patients. The introduction of generic epinephrine auto-injectors has helped address concerns about the high cost of brand-name devices, which could sometimes pose a barrier to access for some patients, particularly those without adequate insurance coverage. By providing lower-cost options, generic versions have made it easier for individuals to obtain the medication they need to manage severe allergies and potentially life-threatening situations.
Furthermore, the availability of generic alternatives has stimulated competition in the market, prompting manufacturers to innovate and improve their products while also driving down prices. This competition has benefited patients, increasing affordability and expanding epinephrine auto-injector options. Overall, the availability of generic epinephrine auto-injectors is a significant advancement in improving access to essential medication for individuals with severe allergies. It underscores the importance of affordability and accessibility in ensuring all patients have access to the life-saving treatments they need.
INDUSTRY RESTRAINTS
High Cost of Auto-injectors & Multiple Alternatives for Injections
The high cost of auto-injectors and the availability of multiple alternatives for injections pose significant challenges for individuals managing various medical conditions, including anaphylaxis, autoimmune diseases, and certain chronic conditions requiring injectable medications. Epinephrine auto-injectors, which are commonly used to treat anaphylaxis, have been subject to increased scrutiny due to their high cost. Brand-name auto-injectors can be prohibitively expensive for many patients, leading to concerns about affordability and access to life-saving medication. Despite efforts to introduce generic versions to the market, the cost of epinephrine auto-injectors remains a barrier for some individuals, particularly those without adequate insurance coverage.
The high cost of auto-injectors and the availability of multiple alternatives for injections highlight the importance of considering factors such as affordability, accessibility, and individual patient preferences when selecting a treatment option. In conclusion, while auto-injectors offer convenience and ease of use for individuals requiring injectable medications, the high cost of these devices underscores the need for greater affordability and accessibility in healthcare. By addressing cost barriers and exploring alternative injection methods, healthcare providers and policymakers can help ensure that all patients have access to the medications they need to manage their conditions effectively.
SEGMENTATION INSIGHTS
INSIGHT BY DOSAGE TYPE
The global epinephrine auto-injector market by dosage type is segmented into high and low doses. The high-dose segment holds the largest share in 2023. The rising incidence/prevalence of anaphylaxis in adults, mainly in the elderly, is the primary factor driving the growth of the high-dose segment of the global epinephrine auto-injector market. Guidelines in several countries for the management of anaphylaxis generally recommend adrenaline as an immediate first-line treatment. As a result, healthcare professionals (HCPs) recommend a higher and safer dose (usually 0.3 mg) of epinephrine auto-injectors when no other adrenaline for intramuscular administration is available.
INSIGHT BY AGE-GROUP TYPE
The global epinephrine auto-injector market by age group is categorized as below 6 years, between 6 - 12 years, and above 12 years. The above 12-year segment shows prominent growth, with the fastest-growing CAGR during the forecast period. This segment is growing due to a rise in the incidence of anaphylaxis emergencies in populations aged above 12 years. Several studies reported anaphylaxis in elderly people tends to be more frequently life-threatening and requires intensified medical intervention. Therefore, to manage the higher risk for fatal outcomes of anaphylaxis in the adult patient group, significantly in elderly people, it is expected that the growth of epinephrine auto-injectors will be driven at a steady rate.
INSIGHT BY END-USER TYPE
By end-user, the individual segment dominates and has the largest share of the global epinephrine auto-injector market. The segment is likely to grow due to the rising demand for self-management of anaphylaxis with epinephrine auto-injectors. Mostly, individuals carry epinephrine auto-injectors for the treatment of sudden anaphylaxis shock.
As the anaphylaxis prevalence is rising rapidly worldwide across all patient groups, self-management is becoming increasingly important for managing anaphylaxis during emergencies at any point in time, irrespective of location. As a result, the individual end-user segment has become a major revenue generator for the global epinephrine auto-injector market. It is likely to grow at the same pace during the forecast period.
KEY QUESTIONS ANSWERED:
- How big is the global epinephrine auto-injectors market?
- What is the growth rate of the global epinephrine auto-injectors market?
- Which region dominates the global epinephrine auto-injectors market?
- What are the key drivers of the global epinephrine auto-injectors market?
- Who are the major players in the global epinephrine auto-injectors market?
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 132 |
| Forecast Period | 2023 - 2029 |
| Estimated Market Value (USD) in 2023 | $2.05 Billion |
| Forecasted Market Value (USD) by 2029 | $3.4 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
Key Vendors
- Viatris
- Teva Pharmaceuticals
- Amneal Pharmaceuticals
- ALK-Abello
- Bausch & Lomb
Other Prominent Vendors
- DMK Pharmaceuticals
- Bioprojet Pharma
- Kaleo
- Novartis
- Sanofi
- Pfizer
- Halozyme Therapeutics
- Crossject SA
- Lincoln Medical
By Geography
- North America
- The U.S.
- Canada
- Europe
- Germany
- The U.K.
- France
- Italy
- Spain
- APAC
- Japan
- China
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
For more information about this report visit https://www.researchandmarkets.com/r/fno106
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
